Skip to content

Hepatitis B testing and treatment rates are low among US veterans

Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis

Andrew Muir speaking at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Photo by Liz Highleyman, hivandhepatitis.com

Young drug injectors on opioid maintenance therapy have lower risk of hepatitis C infection

Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection

Shyam Kottilil speaking at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Photo by Liz Highleyman, hivandhepatitis.com

Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants

Andrew Hill speaking at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting. Photo by Liz Highleyman, hivandhepatitis.com

AbbVie 3D HCV regimen well-tolerated in PEARL trials

Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV

HCV core-antigen testing is a reliable way of detecting acute HCV infections in HIV-positive gay men

People with hepatitis B who have cirrhosis should be prioritised for liver cancer screening